Form 4: Johnson & Johnson Executive Broadhurst Reports Stock Option and Restricted Share Unit Awards

EVP Vanessa Broadhurst reports acquisition of stock options and restricted share units in Johnson & Johnson under the company's Long-Term Incentive Plan.

Summary

• Vanessa Broadhurst, an Executive Vice President at Johnson & Johnson, filed a Form 4 on February 19, 2025, reporting changes in beneficial ownership of company securities.
• The reported transactions include the acquisition of 25,538 employee stock options with an exercise price of $156.15, vesting in three equal annual installments beginning on February 15, 2026, and expiring on February 15, 2035.
• Broadhurst also acquired 1,576 restricted share units (RSUs), vesting in three equal annual installments beginning on February 15, 2026, and converting into common stock on a one-for-one basis upon vesting.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The acquisition of stock options and RSUs suggests continued alignment of the executive's interests with those of the shareholders.
• The vesting schedule of the awards encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Companies like Pfizer (PFE) and Merck (MRK) also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry standards for executives at similar levels within large pharmaceutical companies.
• The specific terms of the awards, such as the exercise price and vesting schedule, are likely determined by Johnson & Johnson's compensation committee based on performance metrics and market benchmarks.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, aligning executive interests with long-term company performance.
• Employees may see this as a standard part of the company's compensation structure.

Key Dates

Keywords

Form 4, Johnson & Johnson, Broadhurst, Stock Options, Restricted Share Units, Executive Compensation, Beneficial Ownership, JNJ